pCMV/SB10 Citations (8)
Originally described in: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.Ivics Z, Hackett PB, Plasterk RH, Izsvak Z Cell. 1997 Nov 14. 91(4):501-10. PubMed Journal
Articles Citing pCMV/SB10
| Articles |
|---|
| Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, Cigliano A, Pascale RM, Calvisi DF, Liu Y, Chen X. Cancer Med. 2018 Dec;7(12):6170-6181. doi: 10.1002/cam4.1777. Epub 2018 Oct 28. PubMed |
A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver.
Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W.
Mol Ther. 2022 Mar 2;30(3):1343-1351. doi: 10.1016/j.ymthe.2022.01.005. Epub 2022 Jan 5.
PubMed
Associated Plasmids |
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate.
Wu YQ, Zhang CS, Xiong J, Cai DQ, Wang CZ, Wang Y, Liu YH, Wang Y, Li Y, Wu J, Wu J, Lan B, Wang X, Chen S, Cao X, Wei X, Hu HH, Guo H, Yu Y, Ghafoor A, Xie C, Wu Y, Xu Z, Zhang C, Zhu M, Huang X, Sun X, Lin SY, Piao HL, Zhou J, Lin SC.
Cell Res. 2023 Nov;33(11):835-850. doi: 10.1038/s41422-023-00874-4. Epub 2023 Sep 19.
PubMed
Associated Plasmids |
| Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT, Shi W, Wang YZ, Wu CY, Xu L, Chen MS, Gao Q, Liu L, Wei Y, Kuang DM. Cancer Cell. 2024 Dec 9;42(12):2082-2097.e10. doi: 10.1016/j.ccell.2024.10.012. Epub 2024 Nov 14. PubMed |
| A multimodal imaging pipeline to decipher cell-specific metabolic functions and tissue microenvironment dynamics. Venkateswaran SV, Kreuzaler P, Maclachlan C, McMahon G, Greenidge G, Collinson L, Bunch J, Yuneva M. Nat Protoc. 2025 Jun;20(6):1678-1699. doi: 10.1038/s41596-024-01118-4. Epub 2025 Jan 29. PubMed |
| Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Liu ZY, Wu CY, Wu RQ, Wang JC, Huang CX, Wang XY, Zhang Y, Zheng L, Chen Y, Lao XM, Chen DP, Kuang DM. Immunity. 2025 Jun 10;58(6):1572-1585.e10. doi: 10.1016/j.immuni.2025.05.006. Epub 2025 Jun 2. PubMed |
| Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma. Cui G, Zhou Y, Liao W, Cossu E, Evert M, Zhang S, Wang J, Deng S, Yonemura A, David L, Xu M, Doumergue JM, Lu X, Yang L, Li J, Liang B, Wang H, Xu H, Zhong S, Deng Y, Calvisi DF, Zhao J, Chen X, Wang X. Cancer Res. 2025 Dec 15;85(24):5049-5065. doi: 10.1158/0008-5472.CAN-25-1615. PubMed |
| GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma. Shi G, Zhang W, Xie F, Shi J, Yan M, He L, Li Z, Xiao Y, Yu D, Cao H, Du H, Qiu Y, Zhang K, Wang S, Li M, Zhang J, Wang Z. Cell Commun Signal. 2025 Oct 15;23(1):440. doi: 10.1186/s12964-025-02427-1. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.